Back to Agenda
SCOTUS DNA Patent Ruling: Implications for the Industry
Session Chair(s)
Paul Sheives, JD, MS
Vice President, Reimbursement and Regulatory Policy
American Clinical Laboratory Association (ACLA), United States
The US Supreme Court has issued its long-awaited decision in Association of Molecular Pathology v. Myriad Genetics, Inc on the patent eligibility of DNA molecules. On its face, the ruling may appear clear cut, but is it? And what will be the effects of the ruling going forward? Our panel will explore the complexity of the issue of DNA patents and the uncertainties raised by the ruling. In a look beyond the specifics, the future implications for the biotech and pharmaceutical sectors will be discussed.
Speaker(s)
Panelist
David S. Resnick, JD, MS
Nixon Peabody, United States
Co-Leader, Patents
Panelist
Hathaway Pease Russell, JD
Foley Hoag LLP, United States
Partner, Registered Patent Attorney
Panelist
Rudolph E. Tanzi, PhD
Massachusetts General Hospital, United States
Head, Genetics and Aging Research Unit; Prof, Neurology, Harvard Medical School
Have an account?